For both sides

Reps, warranties, and compliance indemnities

Federal and state law current as of September 2026 — verify with counsel.

Representations and warranties are the seller's written statements of fact about a cannabis business, and indemnities are the promise to pay if they prove false. Cannabis deals add reps on license standing, track-and-trace accuracy, undisclosed owners and 280E tax positions, and rely on seller-funded protection such as holdbacks and note set-off, because representations and warranties insurance and bank escrow are hard to obtain.

Key takeaways

  • The ABA's 2025 private-target study found 63% of deals used representations and warranties insurance, with a median seller cap of 0.25% of deal value in insured deals against a traditional 8% to 12% in uninsured ones.
  • Cannabis deals mostly sit in the uninsured group: one M&A partner notes both insurance and post-closing bank escrows are rare in the sector.
  • The IRS generally has 3 years to assess tax, and 6 years after a substantial omission of income, so tax reps in an equity deal should survive at least that long.
  • The same ABA study found 81% of agreements include a non-reliance clause and 68% are silent on sandbagging, so buyers should put every important seller statement into the agreement itself.
  • A specific indemnity for a known problem, such as an open notice of violation, is not subject to the basket, cap or knowledge defenses that apply to general reps.

What reps and indemnities do

They allocate the risk of what diligence could not find. The buyer checks what it can. For the rest, the seller states the facts in the agreement, lists exceptions on disclosure schedules, and agrees to pay if a statement was wrong.

Cannabis raises the stakes in two ways. A breach can cost more than money: an undisclosed owner or a falsified tracking record can threaten the license itself. And the usual outside backstops are missing. One M&A partner observes that post-closing escrows are rare in cannabis because national bank escrow agents are unavailable, and that insurers have largely stayed away.

Which cannabis-specific reps should a buyer ask for?

RepWhat the seller statesWhy it matters
License standingEach license is valid, renewed, not subject to suspension, revocation or pending discipline; all fees paidThe license is the asset
Compliance historyAll notices of violation, inspections, fines and corrective plans for a stated look-back period are scheduledRegulators weigh history at renewal and on the buyer’s application; see how compliance history affects value
Ownership and controlEvery owner, financier and party with control or profit rights has been disclosed to the regulator; no side agreementsHidden interests are a revocation risk; see true party of interest rules
Track-and-traceSystem records are accurate and reconcile to physical inventory; no unexplained adjustments or destroyed-product anomaliesDiscrepancies become the new owner’s to explain; see track-and-trace systems and transactions
InventoryProduct is tested, tagged, within date, saleable, and sourced only from licensed suppliersSee inventory and biomass at closing
Local approvalsConditional use permit, local license, host or community agreement in good standing; no unpaid local feesLocal consent is often separate from state approval
PremisesBuilt and operated as shown on the approved floor plan; security system meets the rules; no unapproved modificationsUnapproved changes surface at the buyer’s first inspection
TaxAll federal and state returns filed; 280E applied as required or positions disclosed; excise and sales tax paid; no liens or payment plans undisclosedOften the largest hidden liability
EmployeesBadges current; wage-and-hour compliance; no union petition or undisclosed labor peace obligation
Banking and cashAll accounts disclosed; cash handled and recorded under written procedures; no use of misdescribed accountsA closed bank account can stop operations
Products and marketingNo recalls; packaging, labeling and advertising within state rules

Sellers should not give a flat rep of compliance with all laws. Every plant-touching business violates the federal Controlled Substances Act to some degree, even after the April 2026 rescheduling of state-licensed medical marijuana. The standard fix is to carve federal cannabis law out of the compliance rep and have both parties acknowledge it.

What are market norms for caps, baskets and survival?

The best public data is cross-industry. The ABA’s 2025 Private Target Deal Points Study reviewed 139 agreements from 2024 and early 2025:

TermFinding
Deals using representations and warranties insurance63%, up from 55% in the prior study
Median seller indemnity cap with insurance0.25% of transaction value
Traditional cap without insurance8% to 12% of transaction value over the last decade
Post-closing price adjustment90% of deals; 58% used a separate adjustment escrow
Non-reliance clause81%
Agreement silent on sandbagging68%
Fraud carve-out limited to reps in the agreement70%

SRS Acquiom’s 2026 study of more than 2,300 private-target deals closed from 2020 to 2025 separately reports a marked uptick in escrow size.

Read these with care. The sample is mid-market deals, mostly larger than a single-license cannabis sale, and the insured majority does not describe cannabis. Private cannabis deals resemble the uninsured minority, and buyers often argue for caps above the traditional range on compliance and tax reps because the downside is loss of the license. Reported cannabis holdbacks run 12 to 24 months.

A common architecture:

  • General reps. Deductible basket, cap at a negotiated percentage of price, survival of 12 to 24 months.
  • Fundamental reps such as title, authority, capitalization and brokers: no basket, cap at the purchase price, long survival.
  • Tax reps. Survive until the statute of limitations expires. For federal income tax that is generally 3 years from filing, or 6 years where more than 25% of gross income was omitted.
  • Regulatory compliance reps. Frequently negotiated as a middle tier: higher cap and longer survival than general reps.
  • Fraud. Uncapped, defined as deliberate misstatement in the agreement’s reps.

Illustrative indemnity calculation

A $3,000,000 dispensary sale has a deductible basket of $22,500 (0.75%), a general cap of $300,000 (10%), and a $300,000 holdback for 18 months.

Eight months after closing, the state audits a pre-closing period and assesses $60,000 of excise tax and penalties. At the next inspection, the regulator fines the business $25,000 for pre-closing camera-coverage gaps. Total losses: $85,000.

StepAmount
Total losses$85,000
Less deductible basket$22,500
Recoverable from seller$62,500
Paid from holdback$62,500
Holdback remaining for release at month 18$237,500

If the agreement treated taxes as a separate first-dollar indemnity, the basket would apply only to the $25,000 fine, and recovery would be $60,000 plus $2,500.

Backing the indemnity with money

An indemnity is worth what can be collected. Options, from strongest to weakest for the buyer:

  1. Cash holdback retained by the buyer or a willing escrow agent. See staged closings and escrow pending approval.
  2. Set-off against a seller note or earn-out. Sellers should limit set-off to finally determined claims, or require disputed amounts to be paid into escrow. See seller notes and security interests.
  3. Personal guaranty from the seller’s owners.
  4. An unsecured promise from a selling entity that will distribute its cash and dissolve.

Tax exposure deserves its own reserve, sized by a CPA. In California, a buyer who fails to obtain sales-tax clearance can be personally liable up to the purchase price. Sizing is covered on tax liabilities and holdbacks in a sale.

Knowledge, disclosure and sandbagging

  • Knowledge qualifiers. Sellers want reps limited to what named people actually knew. Buyers should accept this for matters outside the seller’s control, such as threatened investigations, and refuse it for facts the seller should know, such as whether taxes were paid.
  • Disclosure schedules. The schedules are where most of the real negotiation happens. A seller that has run a compliance audit before a sale can disclose precisely and avoid later claims.
  • Sandbagging. Can a buyer claim for a breach it knew about before closing? With 68% of agreements silent, the answer depends on state law. Say it expressly one way or the other.
  • Non-reliance. With 81% of agreements disclaiming reliance on statements outside the contract, anything the buyer was told in a management meeting or a data-room summary should be converted into a rep if it matters.
  • Bring-down. Reps are made at signing and again at closing. In cannabis the gap can be many months, so the seller should have a right to update schedules for new events, and the buyer a right to walk or reprice if the update is material. See regulatory-approval contingencies.

What reps does the buyer give?

Fewer, but they matter to a seller waiting months for approval:

  • Each proposed owner is eligible for licensure, with no disqualifying history, and has disclosed all other cannabis interests that count against ownership caps.
  • Funds are available and come from lawful, documentable sources.
  • The buyer will file on time and respond to regulator requests.
  • If the price includes stock or a note, reps about the issuer’s or maker’s financial condition.

A buyer-side breach that causes denial should cost the buyer its deposit.

Structure changes the package

In an equity purchase the company keeps every historic liability, so the reps and indemnities do all the work. In an asset purchase, excluded-liability language does some of it. The comparison is on asset sale vs membership-interest sale. This page is general education, not legal advice.

Frequently asked questions

What is the difference between a representation and a specific indemnity?

A representation is a statement of fact, for example that the license is in good standing, and the seller pays only if it was untrue and the loss exceeds any basket. A specific indemnity covers a known issue regardless of disclosure: an open investigation, a disputed excise tax period, a former partner's claim. Buyers use it when diligence has already found the problem.

Does disclosing a violation on the schedules protect the seller?

Against a breach-of-rep claim, yes: a rep qualified by a disclosure schedule is not false as to what was disclosed. That is why buyers respond to a significant disclosure by asking for a price reduction, a specific indemnity, or a dedicated holdback. Sellers benefit from disclosing fully, since an undisclosed violation is both a breach and potential evidence of fraud.

How long should the compliance reps survive after closing?

Long enough for problems to surface. Regulators may act on pre-closing conduct when they next inspect or at renewal, so buyers push for survival through at least one full renewal cycle and one annual inventory audit. General cross-industry practice clusters at 12 to 24 months. Tax, ownership and authority reps usually run for the statute of limitations.

Can I get representations and warranties insurance for a cannabis acquisition?

Sometimes, from specialty brokers, but it is not the norm. Mainstream carriers have generally avoided plant-touching deals, policies carry minimum premiums that small transactions cannot absorb, and underwriters exclude the risks buyers care most about, such as federal illegality and known compliance issues. Most private cannabis deals rely on seller indemnities backed by holdbacks or set-off.

If I buy assets instead of equity, do I still need compliance reps?

Yes. An asset deal leaves most historic liabilities with the seller, but the buyer still depends on the license file being clean, the inventory being compliant and correctly tagged, the premises being approved as built, and sales and excise tax being paid, since some of those liabilities can follow the assets or the location.

Sources

  1. Wagner Hicks PLLC — The New Normal in Private M&A: Key Takeaways from the 2025 ABA Deal Points Study (29 Jan 2026) — https://www.wagnerhicks.law/the-new-normal-in-private-ma-key-takeaways-from-the-2025-aba-deal-points-study/
  2. American Bar Association, Business Law Today — Announcing the ABA's 2025 Private Target M&A Deal Points Study (Dec 2025) — https://www.americanbar.org/groups/business_law/resources/business-law-today/2025-december/aba-2025-private-target-mergers-acquisitions-deal-points-study/
  3. SRS Acquiom — Six Key Findings from the 2026 M&A Deal Terms Study — https://www.srsacquiom.com/our-insights/deal-terms-study-key-findings/
  4. Gesmer Updegrove (Sarah Curtis Richmond) — The Unique Challenges of Cannabis M&A Deals — https://gesmer.com/publications/cannabis-ma-deals-the-unique-challenges/
  5. 420 Property — Escrows and Funds Flow in Cannabis Business Sales (12 Aug 2025) — https://www.420property.com/escrows-and-funds-flow-in-cannabis-business-sales/
  6. Cornell Legal Information Institute — 26 U.S.C. 6501 — https://www.law.cornell.edu/uscode/text/26/6501
  7. California Department of Tax and Fee Administration — Revenue and Taxation Code 6812 — https://cdtfa.ca.gov/lawguides/vol1/sutl/6812.html